Presentation is loading. Please wait.

Presentation is loading. Please wait.

Thrombin-activatable fibrinolysis inhibitor and the risk for recurrent venous thromboembolism by Sabine Eichinger, Verena Schönauer, Ansgar Weltermann,

Similar presentations


Presentation on theme: "Thrombin-activatable fibrinolysis inhibitor and the risk for recurrent venous thromboembolism by Sabine Eichinger, Verena Schönauer, Ansgar Weltermann,"— Presentation transcript:

1 Thrombin-activatable fibrinolysis inhibitor and the risk for recurrent venous thromboembolism
by Sabine Eichinger, Verena Schönauer, Ansgar Weltermann, Erich Minar, Christine Bialonczyk, Mirko Hirschl, Barbara Schneider, Peter Quehenberger, and Paul A. Kyrle Blood Volume 103(10): May 15, 2004 ©2004 by American Society of Hematology

2 Kaplan-Meier estimate of the risk for recurrent VTE according to TAFI level.
Kaplan-Meier estimate of the risk for recurrent VTE according to TAFI level. The probability of recurrent VTE after discontinuation of secondary thromboprophylaxis was significantly higher among patients with TAFI levels in the 75th or higher percentile than among patients with lower levels (P = .006, Wilcoxon rank sum test; P = .02, log rank test). Sabine Eichinger et al. Blood 2004;103: ©2004 by American Society of Hematology


Download ppt "Thrombin-activatable fibrinolysis inhibitor and the risk for recurrent venous thromboembolism by Sabine Eichinger, Verena Schönauer, Ansgar Weltermann,"

Similar presentations


Ads by Google